^
BIOMARKER:

HRD

i
Other names: Homologous Recombination Deficiency
Related biomarkers:
HRD
Pancreatic Cancer
ABT-888
Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
HRD
Ovarian Cancer
rucaparib
Sensitive: B - Late Trials
Cancer Med - 4 weeks
HRD
Fallopian Tube Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
HRD
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
HRD
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
HRD
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
HRD
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
HRD
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
HRD
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
HRD
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
HRD
Ovarian Cancer
atezolizumab
Resistant: B - Late Trials
HRD
Ovarian Cancer
CPB
Sensitive: B - Late Trials
HRD
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
HRD
Ovarian Cancer
tislelizumab + pamiparib
Sensitive: C2 – Inclusion Criteria
HRD
Triple Negative Breast Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
HRD
Ovarian Cancer
bevacizumab + niraparib
Sensitive: C2 – Inclusion Criteria
HRD
NSCLC
talazoparib
Resistant: C3 – Early Trials
HRD
Gastric Cancer
nivolumab
Sensitive: C3 – Early Trials
HRD
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
HRD
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
HRD
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials
HRD
Ovarian Cancer
ABT-767
Sensitive: C3 – Early Trials
HRD
Ovarian Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
HRD
Prostate Cancer
talazoparib
Sensitive: C3 – Early Trials
HRD
Triple Negative Breast Cancer
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials